Andere Kunden interessierten sich auch für
![Efficacité et sécurité du dichlorure de radium-223]( "Efficacité et sécurité du dichlorure de radium-223")
Efficacité et sécurité du dichlorure de radium-22330,99 €![Wirksamkeit und Sicherheit von Radium-223-Dichlorid]( "Wirksamkeit und Sicherheit von Radium-223-Dichlorid")
Wirksamkeit und Sicherheit von Radium-223-Dichlorid45,90 €![Eficácia e segurança do dicloreto de rádio-223]( "Eficácia e segurança do dicloreto de rádio-223")
Eficácia e segurança do dicloreto de rádio-22330,99 €![Efficacia e sicurezza del dicloruro di radio-223]( "Efficacia e sicurezza del dicloruro di radio-223")
Efficacia e sicurezza del dicloruro di radio-22330,99 €![Jeffektiwnost' i bezopasnost' dihlorida radiq-223]( "Jeffektiwnost' i bezopasnost' dihlorida radiq-223")
Jeffektiwnost' i bezopasnost' dihlorida radiq-22313,99 €![Determinants and impact of drug shortages in Senegal]( "Determinants and impact of drug shortages in Senegal")
Determinants and impact of drug shortages in Senegal26,99 €![The Anticoagulants¿ Effectiveness and Safety in Long Term Care Patient]( "The Anticoagulants¿ Effectiveness and Safety in Long Term Care Patient")
The Anticoagulants¿ Effectiveness and Safety in Long Term Care Patient42,99 €
Radium-223 dichloride (Ra-223) is an alpha particle-emitting radiopharmaceutical whose licensed indication in patients with castration-resistant prostate cancer with bone metastases (CRPCm) was modified in June 2018, due to the appearance of drug-drug interactions with common drugs in CRPCm such as abiraterone and prednisone/prednisolone. Thus, it was restricted to use in monotherapy or combination with luteinizing hormone-releasing hormone analogues, becoming third-line treatment in patients with CRPCm, for which evidence on its effectiveness and safety in this new context is lacking.